ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 937

Inhibitor Of DNA Binding 1 Mediates Angiogenesis In Rheumatoid Arthritis By Recruitment Of Endothelial Progenitor Cells

Takeo Isozaki1, Alisa E. Koch2, M. Asif Amin1, Ali S. Arbab3, Gautam Edhayan4, Christine M. Ha4, Pei-Suen Tsou4, Sean C. Friday4, David A. Fox4 and Jeffrey H. Ruth4, 1Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 2University of Michigan Medical School, Ann Arbor, MI, 3Diagnostic Radiology, Henry Ford Hospital and Medical Centers, Detroit, MI, 4Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, endothelial cells, transcription factor, transplantation and vasculogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Endothelial progenitor cells (EPCs) are known to induce vasculoproliferative responses within rheumatoid arthritis (RA) synovial tissue (ST). Inhibitor of DNA-Binding 1 (Id1) is a transcription factor shown to be actively transcribed in only progenitor cells, making it a possible marker for identifying EPCs in neovascular responses in RA ST. We previously showed that Id1 is not only expressed in RA STs, but is also secreted and upregulated in RA synovial fluid (SF). The identification of Id1 in RA tissues indicates progenitor cells are active in the RA joint, and may serve as a potential target for limiting neovascularization in the RA ST. This study further examines the cellular sources, angiogenic and chemotactic potential, and cell signaling properties of Id1.

Methods: Severe combined immunodeficient (SCID) mice were implanted with RA ST and allowed to engraft for six weeks. Mice were injected i.v. with fluorescently dye-tagged EPC’s while receiving simultaneous intragraft injections with either human Id1 (10 nM) or PBS. Another group of SCID mice grafted and injected similarly, received intragraft injections of RA SF immunodepleted with either non-specific IgG (“sham depleted”), or Id1 immunodepleted with a neutralizing antibody. For signal transduction analysis, human dermal microvascular endothelial cells (HMVECs) and EPCs were plated and stimulated with human Id1. Cell lysates were made and Western blot analysis was used to determine the kinetics of protein kinase expression. We also examined whether Id1 induces HMVECs to form blood vessels, measured as an increase in plug hemoglobin (Hb) concentration normalized to plug weight, using the mouse Matrigel plug angiogenesis assay. Finally, to determine the cells secreting Id1, we cultured monocytes, HMVECs, EPCs and fibroblasts and measured the supernatants for Id1 expression by ELISA.

Results: There was a significant increase in EPC migration to engrafted RA ST in the SCID mouse chimera to intragraft injections of Id1. Using the same RA ST SCID mouse chimera system, we found that intragraft injections of RA SF immunodepleted of Id1 resulted in a 50% reduction in EPC recruitment compared to mice injected similarly with sham depleted RA SF (*p<0.05). Cell signaling experiments to Id1 showed Jnk was upregulated in both HMVECs and EPCs, and P38 only in EPCs. We also show that Id1 induces in vivo blood vessel formation, and that inhibiting HMVEC associated Jnk with silencing RNA reverses Id1 induced HMVEC vessel formation in Matrigel plugs in vivo. Lastly, we show that monocytes and especially fibroblasts, but not HMVECs and EPCs, actively secrete Id1, indicating that mature fibroblasts may be a primary source of Id1 in RA SF.

Conclusion: Our data indicates that Id1 induces EPC recruitment in the RA ST SCID mouse chimera, and that by depleting RA SF of soluble Id1, we can attenuate EPC migration by 50%. Id1 was also found to be potently angiogenic in the mouse Matrigel angiogenesis assay, and activates Jnk signaling pathways in HMVECs and EPCs. Lastly, we found that fibroblasts actively secrete Id1 and may be a primary source for its expression in SF. These studies identify Id1 as both a regulatory transcription factor and a unique angiogenic target within the RA synovium.


Disclosure:

T. Isozaki,
None;

A. E. Koch,

Eli Lilly and Company,

3;

M. A. Amin,
None;

A. S. Arbab,
None;

G. Edhayan,
None;

C. M. Ha,
None;

P. S. Tsou,
None;

S. C. Friday,
None;

D. A. Fox,
None;

J. H. Ruth,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibitor-of-dna-binding-1-mediates-angiogenesis-in-rheumatoid-arthritis-by-recruitment-of-endothelial-progenitor-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology